Study of SRF617 in Patients With Advanced Solid Tumors

SRF617 prevents CD39 mediated conversion of adenosine triphosphate (ATP) and adenosine diphosphate (ADP) to adenosine monophosphate (AMP) and phosphate, leading to an increase in extracellular ATP and a reduction in adenosine levels within the tumor microenvironment (TME). There is an important role for extracellular ATP and adenosine in cancer maintenance and progression, and maintaining high levels of ATP (and low levels of adenosine) in the TME may have anticancer therapeutic activity.

Gemcitabine as an intravenous (IV) infusion

Albumin-bound paclitaxel as an IV infusion

Pembrolizumab as an IV infusion .